NRTSF Nobilis Health Corp. (PNK) falls to $0.00003 on 09 Mar 2026: watch downside risk

NRTSF stock plunged intraday on 09 Mar 2026 as share price collapsed to USD 0.000025 during regular market hours in the United States (PNK). We saw volume of 657.00 shares and a dramatic one-day change of -99.97% that followed a prior close at USD 0.08041. This extreme move puts liquidity, market cap and potential delisting risks in focus for traders and investors, and frames why NRTSF is one of today’s top losers in the healthcare micro-cap cohort.

NRTSF stock: intraday price action and volume

NRTSF stock traded between a day low of USD 0.000001 and a day high of USD 0.000025 on 09 Mar 2026. The print shows a market cap near USD 1,956.00 and average daily volume of 31,802.00, highlighting a liquidity squeeze. One clear sign: the relative volume was 0.02, meaning typical buyers were absent and price swings amplified on low flow.

NRTSF stock: fundamentals and valuation snapshot

Nobilis Health Corp. (NRTSF) operates outpatient surgery centers in the Healthcare sector and reports EPS of 0.02. Key metrics show book value per share of 2.54 and revenue per share TTM of 3.85. Reported enterprise value is USD 114,266,956.00, which contrasts sharply with a market cap of USD 1,956.00, signaling market pricing anomalies versus reported fundamentals.

NRTSF stock: technicals, liquidity and trading risk

Technicals show extreme readings: RSI at 100.00 and ADX at 100.00, which typically flag abnormal moves on tiny sample sizes. Average volume over 50 days is 1.42e-05 price average, and current volume of 657.00 is far below the 50-day flow. Tight trading ranges can cause order execution failure and wide spreads for retail traders.

NRTSF stock: sector context and catalysts

Nobilis sits in the Medical – Care Facilities industry inside Healthcare. Sector trends show stable demand for outpatient services, but micro-cap names face higher sensitivity to reimbursement changes and investor sentiment. Near-term catalysts would include verified SEC filings, earnings clarity, or a corporate plan to restore liquidity.

NRTSF stock: Meyka AI grade and analyst framing

Meyka AI rates NRTSF with a score out of 100: 67.20 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects mixed fundamentals versus severe market pricing stress. Investors should note this grade is informational and not financial advice.

NRTSF stock: balance-sheet signals and risks

Balance-sheet indicators show current ratio 2.12 and debt to equity 0.91, giving some short-term coverage. But enterprise value over EBITDA is 3.34, and net debt to EBITDA near 3.34 increases leverage risk. Receivables days are 176.00, which can strain cash conversion in a low-liquidity trading regime.

Final Thoughts

NRTSF stock is a severe top loser on 09 Mar 2026 after a near-total intraday collapse to USD 0.000025. The move exposes thin liquidity, spread risk and potential delisting or quotation issues for Nobilis Health Corp. (PNK) in the United States. Meyka AI’s forecast model projects a year-end reference scenario at USD 0.00010, implying an implied upside of +300.00% versus the current print. That projection is model-driven and assumes restored trading mechanics and confirmed filings. Practically, traders face wide execution risk and should size positions conservatively. We note core fundamentals still show revenue per share 3.85 and book value per share 2.54, but market pricing has decoupled from those metrics. For action, watch official filings and liquidity improvements before adding exposure. Meyka AI provides this as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.